Drug intelligence / Profile preview

semaglutide + aldesleukin

Development stage: Phase 2
Lead developer: Methodist Hospital Research Institute
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
Administration: Subcutaneous

Overview

semaglutide + interleukin-2 is an investigational combination therapy comprising the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and the recombinant cytokine interleukin-2 (aldesleukin). Currently being evaluated in Phase Ib clinical trials for Alzheimer's disease, the combination aims to address neuroinflammation through a dual mechanism: semaglutide provides neuroprotective and anti-inflammatory effects via GLP-1 receptor activation, while low-dose interleukin-2 selectively expands and restores the function of regulatory T cells (Tregs). This multimodal approach is designed to dampen harmful immune responses and improve cellular survival in the brains of patients with Alzheimer's disease. The therapy is being developed by The Methodist Hospital Research Institute.

Other names: semaglutide + interleukin-2IL-2 and SemaglutideIL2 and SemaglutideIL 2 and SemaglutideSemaglutide Plus IL-2

Targets

GLP1R (GLP-1R)IL-2R (Interleukin-2/interleukin-15 receptor complex)IL-2RA (Interleukin-2 receptor subunit alpha)

Beyond the preview

Go deeper on semaglutide + aldesleukin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on semaglutide + aldesleukin.